Translating exciting science into viable business strategies and thereby enabling drug developers to bring new therapeutic options to patients around the globe has been the key driver of Sarah’s career. As a strategy consultant she has successfully led a broad variety of international projects ranging from early preclinical strategies to broad M&A screens.

She studied Pharmacy at the University of Heidelberg and Molecular Genetics in Zaragoza, Spain, gaining experience as both a hospital and community pharmacist before joining Novartis Institutes of Biomedical Research. Sarah earned her PhD in Immuno-Oncology, developing innovative CAR-modified lymphocytes, and gained expertise in cell therapy regulation and manufacturing, which she now shares with clients globally.